According to the company, the test has shown to be more sensitive and accurate than a COVID-19 anterior nasal swab test in the firm's EUA validation study.
The seven technologies feature different methods, including CRISPR and microfluidics, and can be performed in many settings and with a variety of sample types.
The firm saw $109 million in sales of its COVID-19-related products, including nearly $53 million in sales of its Lyra SARS-CoV-2 molecular diagnostic assay.
The company is employing Guardant360 in a Phase III trial assessing the efficacy of the drug both in a larger population and in women who test positive for ESR1 mutations.
The firm reported that revenues from screening products fell 34 percent year over year, but that it took in $34.6 million in revenues from COVID-19 testing.
Researchers have developed a method, called MemorySeq, to identify genes transcriptome-wide whose expression fluctuations persist for several cell divisions.
SomaLogic will analyze more than 40,000 samples, including from Amgen clinical trials, using its SomaScan platform, which measures up to 5,000 proteins.
Strong demand for the firm's COVID-19 molecular tests for the Panther and Panther Fusion platforms offset revenue declines in other areas of the business.
With revenues of $143,000, the company incurred a net loss of $9.1 million, or $0.14 per share, for the quarter, exceeding the consensus Wall Street estimate.
The group will use Akoya's Phenoptics platform to discover biomarkers for selecting neoadjuvant and adjuvant immunotherapies for early-stage breast cancer patients.
Through the partnership, Strata will use its next-generation sequencing test to identify advanced cancer patients with mutations in the MAPK signaling pathway.
The collaboration seeks to develop RNA-based signatures that could help oncologists predict disease progression and guide the use of precision therapies.
MaviDx will develop, validate, secure regulatory approvals for, and commercialize its SARS-CoV-2 and other infectious disease tests, including for influenza, on Veracyte's nCounter system.
According to the Wall Street Journal, the Food and Drug Administration may soon issue an Emergency Use Authorization for convalescent plasma to treat COVID-19 patients.
